Key result
CILP1 plasma concentration was a good predictor of right ventricular ejection fraction < 40% in patients with ischemic cardiomyopathy (AUC = 0.72), with an optimal cut-off value of 3545 pg/ml.
Why the study?
The study was conducted to evaluate cartilage intermediate layer protein 1 (CILP1) as a biomarker of right ventricular dysfunction in patients with ischemic cardiomyopathy.
Does CILP1 plasma concentration predict right ventricular dysfunction in patients with ischemic cardiomyopathy?
Observational (n=128)
Does CILP1 plasma concentration predict right ventricular dysfunction in patients with ischemic cardiomyopathy?
CILP1 is a potential novel biomarker for identifying prognostically relevant right ventricular dysfunction in patients with ischemic cardiomyopathy.
CILP1 may identify RV dysfunction in ischemic cardiomyopathy; cross-sectional data leave open its clinical utility and need prospective validation.
The aim of this study was to evaluate the cartilage intermediate layer protein 1 (CILP1) as a biomarker of right ventricular dysfunction in patients with ischemic cardiomyopathy (ICM). CILP1 plasma concentrations were measured in 98 patients with ICM and 30 controls without any cardiac abnormalities. All participants underwent cardiac magnetic resonance imaging. Median CILP1 concentrations were higher in ICM than in controls. In the tertile analysis, low right ventricular ejection fraction (RVEF) and high right ventricular end‐systolic volume index and N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) were associated with higher CILP1 levels in ICM. However, there were no associations between CILP1 concentrations and left ventricular (LV) parameters in this group. In receiver‐operating characteristic (ROC) analysis CILP1 was a good predictor of RVEF < 40% with an optimal cut‐off value of 3545 pg/ml in ICM, whereas it was not predictive of LV ejection fraction (LVEF) < 40% (area under the curve [AUC] = 0.57) There was no significant difference between the ROC curves of CILP1 (AUC = 0.72) and NT‐proBNP (AUC = 0.77) for RVEF < 40% ( p = 0.42). In multivariable regression analysis, RVEF was the only independent predictor of elevated CILP1. CILP1 and LVEF were the only independent predictors of RVEF < 40% in ICM. Our analysis demonstrates the potential role of CILP1 as a novel cardiac biomarker of prognostically relevant RV dysfunction in patients with ICM.
No takes yet. Share an insight, caveat, or question.
Keranov et al. (2022) conducted an observational in Ischemic cardiomyopathy (n=128). CILP1 plasma concentration vs. Controls without cardiac abnormalities was evaluated on Prediction of right ventricular ejection fraction < 40% (AUC 0.72). CILP1 plasma concentration was a good predictor of right ventricular ejection fraction < 40% in patients with ischemic cardiomyopathy (AUC = 0.72), with an optimal cut-off value of 3545 pg/ml.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: